:,

Wuguang Chang1,2, Bin Luo1, Zhesheng Wen3

  • 1Department of Thoracic Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.

PubMed
概括

一种新的编程细胞死亡 (PCD) 签名预测了肺腺癌 (LUAD) 的不良预后和免疫治疗耐药性. 基因NAPSA显示出预测LUAD患者免疫治疗疗效的潜力.